id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10172 R37167 |
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
7.53 [0.36;158.21] C excluded (control group) |
0/80 2/2,997 | 2 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10042 R36303 |
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 7.20 [0.45;116.14] C | 0/80 1,637/1,875,733 | 1,637 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9136 R31378 |
Lowe (Phenobarbital) (Controls unexposed, disease free), 1973 | Cleft lip and/or cleft palate | 1st trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
12.40 [1.68;91.45] C excluded (control group) |
1/53 49/31,632 | 50 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9137 R31380 |
Lowe (Phenobarbital) (Controls unexposed, sick), 1973 | Cleft lip and/or cleft palate | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: No | 6.44 [0.26;160.73] C | 1/53 0/111 | 1 | 53 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 6.86 [0.84;56.26] | 1,638 | 133 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9136, 10172